(Q44408807)

2 December 2017

title

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels (English)

1 reference

2 December 2017

1 reference

1 reference

1 reference

2 December 2017

Stefan Zeuzem

1 reference

2 December 2017

0 references

Teerha Piratvisuth

1 reference

2 December 2017

Harry L A Janssen

1 reference

2 December 2017

Milan J Sonneveld

1 reference

2 December 2017

Ji-Dong Jia

1 reference

2 December 2017

Edward Gane

1 reference

2 December 2017

Qing Xie

1 reference

2 December 2017

E Jenny Heathcote

1 reference

2 December 2017

Henry L-Y Chan

1 reference

2 December 2017

language of work or name

English

0 references

publication date

29 July 2013

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

page(s)

872-880

1 reference

Hepatocellular carcinoma and hepatitis B virus

2 December 2017

cites work

1 reference

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

21 January 2018

1 reference

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.

21 January 2018

1 reference

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.

21 January 2018

1 reference

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

21 January 2018

1 reference

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

21 January 2018

1 reference

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

21 January 2018

1 reference

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

21 January 2018

1 reference

Further Analysis Is Required to Identify an Early Stopping Rule for Peginterferon Therapy That Is Valid for All Hepatitis B e Antigen–Positive Patients *†#

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.26436

1 reference

2 December 2017

1 reference